Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EffRx signs licensing agreement with Nycomed
Under the terms of the agreement, EffRx will receive from Nycomed upfront and milestone payments up to $59 million. EffRx will in addition be granted double-digit royalties on
Under the terms of the agreement, EffRx will receive from Nycomed upfront and milestone payments up to $59 million. EffRx will in addition be granted double-digit royalties on
The safety and efficacy of Savella was established in two US pivotal Phase III clinical trials involving over 2,000 patients with fibromyalgia. The studies showed that Savella doses
Mr Pilnik has spent the past 25 years with Eli Lilly, most recently as group vice president and chief marketing officer and a member of the company’s operations
The preferred vendor agreement will streamline the Intertek purchasing process for PerkinElmer products worldwide and is expected to be valued at several million dollars. “As an organization focused
As part of the agreement, the two companies will jointly market their services to biomedical companies, insurers and government agencies worldwide. World Health Information Science Consultants (WHISCON) will
This is a single pivotal study designed to support applications to market ASA404 for lung cancer patients who have received one previous round of treatment. A separate, ongoing
This approval enables the company to market its line of bioresorbable implants for bone and/or soft tissue repair in the EU. Orthomimetics’s family of products was developed during
In all available and eligible patients assessed at 12 months post-treatment, more than seven times as many positive responses to treatment were documented in patients who received the
Under this partnership, BioLeap and Jubilant will integrate BioLeap’s computational fragment based drug design platform with Jubilant’s expertise in chemistry, biology and crystallography to offer a highly competitive
Regulatory approvals have also been obtained and dosing will begin shortly in two additional trials: a randomized Phase II study to evaluate NKTR-102 versus irinotecan in second-line colorectal